Founded in 2007, Fulcrum is a biopharmaceutical company developing a drug carrier delivery platform for therapeutic drugs based on the SP-1 protein class.

Fulcrum’s platform is based on nano-bio materials, which permit to target pathology-linked conditions such as cancer, osteoarthritis and Alzheimers.

The company has an irrevocable, exclusive, and unlimited worldwide license from the Hebrew University to research, develop and apply the SP-1 protein.

The company completed feasibility studies in mice and has begun efficiency tests in animals and intends to conduct an additional series of animal tests to further examine and demonstrate the efficiency and reduced toxicity of SP-1 compounded antineoplastics.

Fulcrum has been granted patents on its core technology’s composition of matter and method of production.